DOKUMEN123.COM

$C min$ is a term used in pharmacokinetics for the minimum blood plasma concentration reached by a drug during a dosing interval, which is the time interval between administration of two doses. This definition is slightly different from $C trough$ , the concentration immediately prior to administration of the next dose.^[1] $C min$ is the opposite of $C max$ , the maximum concentration that the drug reaches. $C min$ must be above certain thresholds, such as the minimum inhibitory concentration (MIC), to achieve a therapeutic effect.^[2]

In most cases $C min$ is directly measurable. At steady state the minimum plasma concentration can also be calculated using the following equation:^[3] $C_{min}={\frac {SFDk_{a}}{V_{d}(k_{a}-k_{e})}}\times \left({\frac {e^{-k_{e}\tau }}{1-e^{-k_{e}\tau }}}-{\frac {e^{-k_{a}\tau }}{1-e^{-k_{a}\tau }}}\right)$

S

= Salt factor

F

= Bioavailability

D

= Dose

k e

= Elimination rate constant

k a

= Absorption rate constant

V d

= Volume of distribution

τ

= Dosing interval

$C min$ is also an important parameter in bioavailability and bioequivalence studies, it is part of the pharmacokinetic information recommended for submission of investigational new drug applications.^[4]

References

^ Weimann HJ, Cawello W, Brett M, Zimmermann H, Pabst G, Sierakowski B, et al. (1999). "Drug concentrations and directly derived parameters". Parameters for Compartment Free Pharmacokinetics: Standardisation of Study Design, Data Analysis and Reporting. Aachen, Germany: Shaker-Verlag. pp. 25–40. ISBN 978-3-8265-4767-6. OCLC 44511664. (pages 31–34 in 2003 edition)
^ Dalton BR (February 2023). "What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value". Microorganisms. 11 (3): 567. doi:10.3390/microorganisms11030567. PMC 10051726. PMID 36985141.
^ Dhillon S, Gill K (2006). "Basic pharmacokinetics". Clinical pharmacokinetics (PDF). Pharmaceutical Press. pp. 1–44. ISBN 9780853695714. Archived from the original (PDF) on 29 March 2018.
^ "Bioavailability and Bioequivalence, Studies for Orally Administered Drug Products — General Considerations" (PDF). Guidance for Industry. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration. March 2003. Archived from the original (PDF) on 19 March 2013.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[1] Weimann HJ, Cawello W, Brett M, Zimmermann H, Pabst G, Sierakowski B, et al. (1999). "Drug concentrations and directly derived parameters". Parameters for Compartment Free Pharmacokinetics: Standardisation of Study Design, Data Analysis and Reporting. Aachen, Germany: Shaker-Verlag. pp. 25–40. ISBN 978-3-8265-4767-6. OCLC 44511664. (pages 31–34 in 2003 edition)

[2] Dalton BR (February 2023). "What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value". Microorganisms. 11 (3): 567. doi:10.3390/microorganisms11030567. PMC 10051726. PMID 36985141.

[3] Dhillon S, Gill K (2006). "Basic pharmacokinetics". Clinical pharmacokinetics (PDF). Pharmaceutical Press. pp. 1–44. ISBN 9780853695714. Archived from the original (PDF) on 29 March 2018.

[4] "Bioavailability and Bioequivalence, Studies for Orally Administered Drug Products — General Considerations" (PDF). Guidance for Industry. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration. March 2003. Archived from the original (PDF) on 19 March 2013.

[1]

[2]

[3]

[4]

DOKUMEN123.COM

Cmin

References

Content Disclaimer